Examination of the spleen: Anatomy of the spleen
Author: Prof. Dr. Christoph F. Dietrich
©Falk Foundation e.V., Freiburg. All rights reserved.
Post-COVID-19 irritable bowel syndrome: Hospitalized patients with COVID-19 had fewer problems with constipation and hard stools at 12 months after acute COVID-19 infection. In contrast, patients with COVID-19 had significantly higher rates of irritable bowel syndrome compared to controls.
Tsai PC et al, J Hepatol. 2023;78(2):281–92
Metformin reduces risk for hepatocellular carcinoma in individuals with cured chronic hepatitis C and diabetes mellitus: Individuals with diabetes mellitus have a significantly higher risk for hepatocellular carcinoma (HCC) after successful antiviral therapy for hepatitis C. A recent large cohort study from Taiwan suggests that metformin may significantly reduce HCC risk in these individuals.
Demory A et al, Hepatology. 2023;77(2):430–42
Body weight change and duration of estrogen exposure modulate evolution of hepatocellular adenomas after discontinuation of contraception: A recent retrospective study indicates that weight reduction leads to regression of liver adenomas. In addition, evolution can be predicted based on the duration of estrogen exposure.
Goyal L et al, N Engl J Med. 2023;388(3):228–39
Futibatinib as future treatment candidate for FGFR2-rearranged intrahepatic cholangiocarcinoma: Intrahepatic cholangiocarcinoma still has a very poor prognosis. A recent early clinical study indicates that the FGFR inhibitor futibatinib could be a promising therapy option in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma.
Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: Vonoprazan was non-inferior, but superior to the proton-pump inhibitor lansoprazole in healing and maintenance of healing of erosive esophagitis in a randomized trial. This benefit was seen predominantly in more severe erosive esophagitis.
Erlotinib to reduce polyp burden associated with familial adenomatous polyposis (FAP): Weekly erlotinib dosing over 6 months resulted in markedly lower duodenal polyp burden and modestly reduced lower gastrointestinal polyp burden after 6 months in a single-arm phase 2 trial.
Exit strategies for Crohn’s disease treated with combination therapy with infliximab and immunosuppressant: Results of a randomized trial indicate that patients with Crohn’s disease in sustained steroid-free remission under combination therapy with infliximab and immunosuppressant have an increased risk of disease flares following discontinuation of infliximab. In contrast, de-escalation of immunosuppressant therapy was generally well tolerated and safe.
Targeted therapy of advanced KRAS p.G12C mutated pancreatic cancer: The KRAS G12C inhibitor sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had received previous chemotherapy.
Inflammation of the Upper and Lower GI Tract: Common mechanisms and Treatments or Important Differences?
April 28 – 29, 2023, Bordeaux, France